- Healthcare 150
- Posts
- Hospital Margins Tighten as Uninsured Patients Rise
Hospital Margins Tighten as Uninsured Patients Rise
Healthcare is becoming increasingly polarized: capital, patients, and AI adoption are flowing toward the strongest platforms.
Santiago Morazzani & Valentin Monza
August 06, 2026
Good morning, ! This week we’re diving into the uninsured increase becoming a nightmare for hospitals, AI adoption in APAC, and Expedition Therapeutics betting big on COPD.
Want to advertise in Healthcare 150? Check out our ad platform, here.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
THE 60-SECOND BRIEF
The week's pulse in healthcare investing.
Hospital economics are coming under pressure. The expiration of enhanced ACA subsidies is driving uninsured rates higher, increasing bad debt and uncompensated care.
Biotech capital remains highly selective. Expedition Therapeutics' $115M Series B reinforces that investors are backing differentiated science targeting large, underserved markets.
Healthcare AI is entering its commercialization phase. In Asia-Pacific, consumers increasingly embrace AI when it enhances—not replaces—clinicians, creating fertile ground for scalable healthcare platforms.
Strategic buyers continue to pay for quality. From Thorne to Hinge Health's expansion into digestive care, capital is concentrating around category leaders and platform-building acquisitions.
Execution is separating the winners. Whether in providers, biotech, or digital health, businesses solving real clinical and operational challenges are attracting both capital and strategic interest.
You’re invited: Where AI Meets Private Equity
Artificial intelligence has moved beyond experimentation. The real question for private equity firms is no longer whether to adopt AI, but how to turn it into measurable value across the investment lifecycle.
On November 18, PE150 and CapLink Group will host the AI / Data & Insight Private Capital Breakfast, an invitation-only gathering at London's May Fair Hotel that will bring together operating partners, deal teams, portfolio executives, and technology leaders to discuss what AI adoption actually looks like inside private equity.
The morning will feature three practitioner-led discussions:
AI Into Value Creation — How leading firms are transforming AI from dashboards into repeatable value creation playbooks across portfolio companies. Sponsored by Exact Insight.
AI Across the Investment Lifecycle — Practical applications spanning sourcing, due diligence, investment decisions, and portfolio management. Sponsored by our M&A Technology Partner Datasite.
Building the AI-Enabled Private Equity Firm — The operating models, data strategies, and organizational capabilities required to scale AI successfully.
Interested in attending? Register or request the full agenda here.
Interested in sponsoring? Email [email protected]
HEADLINE OF THE WEEK
The Uninsured Are Returning. Hospitals Are Feeling It First.
The expiration of enhanced Affordable Care Act subsidies is beginning to reshape hospital economics. For-profit operators including HCA Healthcare, Community Health Systems, and Universal Health Services report that patients losing marketplace coverage are not migrating to lower-cost plans. They are becoming uninsured altogether.
The financial impact is already visible. HCA expects more than $1 billion in earnings pressure this year, while uncompensated care climbed 29% year over year to $1.45 billion. Community Health Systems reported an approximately 20% increase in uninsured patients versus 2025, suggesting the trend accelerated through the second quarter.
Why it matters: This extends beyond hospital margins. A growing uninsured population typically delays elective procedures, increases bad debt, and raises patient acuity as individuals seek care later. That combination pressures provider profitability while increasing system-wide costs.
Bottom line: The ACA subsidy expiration is evolving from a policy story into an earnings story. If current trends persist, investors should expect greater scrutiny on uncompensated care, bad debt, and hospital margin resilience over the coming quarters. (More)
MICROSURVEY
Which hospital KPI will investors watch most closely in H2 2026? |
DEAL OF THE WEEK
Expedition Therapeutics Bets Big on a New Approach to COPD
Biotech investors continue to show that differentiated science still attracts capital. Expedition Therapeutics closed an oversubscribed $115 million Series B to advance EXPD-101, a next-generation oral DPP1 inhibitor targeting chronic obstructive pulmonary disease (COPD). The round was backed by an elite syndicate including General Atlantic, Novo Holdings, Sofinnova Investments, Forbion, and Sanofi Ventures, highlighting continued appetite for high-conviction respiratory assets despite a selective biotech funding environment.
EXPD-101 is designed to reduce the excessive neutrophil-driven inflammation responsible for COPD exacerbations without broadly suppressing the immune system—a key limitation of current anti-inflammatory therapies. With COPD affecting more than 390 million people worldwide and remaining one of the leading causes of death globally, even incremental improvements in exacerbation rates could translate into a multibillion-dollar commercial opportunity.
Why it matters: Capital is flowing toward platform companies with clinically validated assets addressing large, underserved markets. Following Merck's $10 billion acquisition of Verona Pharma, investors are increasingly viewing respiratory disease as one of biotech's most attractive therapeutic categories, with innovative COPD therapies emerging as the next battleground for strategic M&A.
DEAL TRACKER
$289M | Attovia Therapeutics IPO
Attovia Therapeutics raised $289M in its Nasdaq IPO to advance its ATTOBODY platform and pipeline of multispecific biologics, including a potential next-generation challenger to Sanofi/Regeneron's blockbuster Dupixent. Read more
$105M | Hinge Health → Cylinder Health
Hinge Health acquired Cylinder Health for $105M, expanding beyond musculoskeletal care into digestive health as it builds a broader virtual specialty care platform. Read more
Sheridan Capital Partners → Carolina Components Group
Sheridan Capital Partners acquired Carolina Components Group, a supplier of single-use components and fluid management solutions for biopharmaceutical manufacturing. Financial terms were not disclosed. The deal strengthens Sheridan's exposure to life sciences manufacturing infrastructure. Read more
$3.8B | Procter & Gamble → Thorne
P&G agreed to acquire Thorne from L Catterton for $3.8B, expanding its presence in premium supplements and personalized health while marking one of the year's largest healthcare PE exits. Read more
REGIONAL FOCUS
Asia-Pacific’s Healthcare AI Adoption Reaches an Inflection Point
Asia-Pacific is becoming one of the most important testing grounds for AI-enabled healthcare. Unlike more mature markets, the region combines two powerful forces: rising consumer expectations and structural capacity constraints.
According to Bain's Asia-Pacific Front Line of Healthcare 2026 report, nearly three-quarters of consumers across the region feel comfortable with at least one AI-enabled healthcare application. But that comfort is conditional. Acceptance is highest where AI supports the clinician — taking notes during appointments (57%) or analyzing exam results for a doctor to review (55%) — and drops sharply where AI replaces the physician, such as making the diagnosis (39%) or acting as the doctor itself (37%).
That distinction is where APAC stands apart. Compared with US consumers, people in the region are consistently more willing to let AI take on the higher-stakes, physician-replacing roles — 37% vs. 28% comfortable with "AI becomes my doctor," and 39% vs. 34% with AI-led diagnosis. In a region facing acute clinician shortages, that openness reads less like enthusiasm and more like a response to scarcity.
The timing is not accidental. Healthcare systems across APAC are under pressure from aging populations, fragmented care journeys, and thin physician density — many emerging markets sit well below the WHO's recommended 2.5 doctors per 1,000 people. Bain found that 95% of consumers now want a single touchpoint to manage their healthcare, up from 70% in 2019, underscoring a widening gap between patient expectations and current delivery models.
For investors, the opportunity is shifting from AI experimentation to healthcare infrastructure. The winners will likely not be standalone AI tools, but platforms that embed AI into clinical workflows, patient navigation, and care coordination.
Bottom line: APAC may become the proving ground for AI healthcare models that combine scalability, affordability, and better patient experiences — creating new opportunities across digital health, provider enablement, and healthcare IT.
